Technology
Health
Biotechnology

Unum Therapeutics

$2.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.11 (-4.21%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell UMRX and other stocks, options, ETFs, and crypto commission-free!

About UMRX

Unum Therapeutics Inc. Common Stock, also called Unum Therapeutics, is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Read More The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Employees
56
Headquarters
Cambridge, Massachusetts
Founded
2014
Market Cap
78.61M
Price-Earnings Ratio
Dividend Yield
Average Volume
335.78K
High Today
$2.68
Low Today
$2.46
Open Price
$2.61
Volume
99.43K
52 Week High
$17.66
52 Week Low
$1.88

Collections

Technology
Health
Biotechnology
Medical
Therapy
Biopharmaceutical
Cancer Prevention
Pharmaceutical

UMRX News

MarketWatchJul 5

Unum Therapeutics Inc.

103

More UMRX News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.